A PHASE I/II DOUBLE-BLIND CONTROLLED TRIAL TO DETERMINE THE SAFETY AND IMMUNOGENICITY OF HIV-1 MN RGP160 IMMUNO AG VACCINE THERAPY IN HIV-INFECTED INDIVIDUALS WITH GREATER THAN OR EQUAL TO 500/MM3 CD4+ T CELLS AND 200-400/MM3 CD4+ T CELLS: